ReviewCellular and molecular neurobiology2025
Neuroimmune Dysregulation and AI-Driven Therapeutic Strategies in Alzheimer's Disease.
Review in Cellular and molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microglia-Astrocyte Cooperation and Peripheral T Cells in Alzheimer's Disease: State-of-the-Art and Treatment Perspectives.International journal of molecular sciences · 2026Review
- AI-driven insights into protein misfolding and innate immunity in neurodegenerative diseases.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroimmune interactions have arisen as central contributors to the pathogenesis and progression of Alzheimer’s disease. The exacerbation of neuronal dysfunction in Alzheimer’s disease is collectively contributed by dysregulation of astrocytic and microglial responses, invasion of peripheral immune cells, and chronic inflammation. A mechanistic understanding of molecular, cellular, and systems-level neuroimmune interactions in Alzheimer’s disease is enabling rational, testable therapeutic strategies. We have tried to extensively address the molecular regulation of glial activation, inflammasome signaling, and immune cell invasion in Alzheimer’s disease. This review highlights microglial metabolic reprogramming and lipid-metabolism dysregulation as major drivers of neuroinflammation. Existing and future therapeutic approaches to glial activation, immunometabolism, and inflammasome signaling are thoroughly reviewed, together with novel strategies involving stem cell-derived exosomes and peripheral immunity modulation. Artificial intelligence and machine learning technologies are the latest game-changing technologies in unraveling neuroimmune complexity, discovering biomarkers, simulating disease courses, and speeding up drug discovery. Integration of multi-omics information and AI-based predictive models is suggested as a critical strategy for the development of precision medicine strategies in neuroimmune therapeutics. Advancements in neuroimmune research, coupled with computational biology technological advancements, hold the promise to transform the therapeutic environment for Alzheimer’s disease. Multitargeted, integrated interventions and data-driven strategies are set to overcome current limitations and advance closer to effective, personalized therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.